Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities (2023 - 2026)

Recursion Pharmaceuticals has reported Total Non-Current Liabilities for 4 years, with the latest figure at $312.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 14.67% year-over-year to $312.7 million; the trailing twelve-month figure through Mar 2026 stood at $312.7 million (down 14.67% YoY), and the FY2025 full-year result was $341.2 million, down 16.6% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $312.7 million, down from $341.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $409.1 million in Q4 2024, with the low at $188.4 million in Q2 2024.
• Historically, Total Non-Current Liabilities has averaged $304.5 million across 4 years, with a median of $341.2 million in 2025.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 115.01% — and 2025, when it retreated 16.6%.
• Recursion Pharmaceuticals' Total Non-Current Liabilities stood at $190.3 million in 2023, then surged by 115.01% to $409.1 million in 2024, then dropped by 16.6% to $341.2 million in 2025, then fell by 8.34% to $312.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $312.7 million (Q1 2026), $341.2 million (Q4 2025), and $351.5 million (Q3 2025), per Business Quant data.